Pharmacyclics I Janssen- COMMERCIAL
IMBRUVICA® is approved for adults with CLL, SLL, and WM.
WARNINGS AND PRECAUTIONS:
Hemorrhage, infections, cytopenias, cardiac arrhythmias and cardiac failure, hypertension, second primary malignancies, tumor lysis syndrome, and embryo-fetal toxicity.
ADVERSE REACTIONS:
The most common adverse reactions (≥30%) in patients with B-cell malignancies (MCL, CLL/SLL, WM and MZL) were thrombocytopenia (54.5%)*, diarrhea (43.8%), fatigue (39.1%), musculoskeletal pain (38.8%), neutropenia (38.6%)*, rash (35.8%), anemia (35.0%)*, and bruising (32.0%).
*Treatment-emergent decreases (all grades) were based on laboratory measurements.
Please see the full Important Safety Information in the video below and the full Prescribing Information available at https://imbruvica.com/prescribing-information.
Brands: https://events.jspargo.com/ASCO21/CUSTOM/IMBRUVICA_ASCO_BANNER_2_LOGO_04_21_21.png
Show Specials
Press Releases